Tag Archives: Moderna

Reuters reports: Moderna said on Wednesday its experimental COVID-19 vaccine induced immune responses in older adults similar to those in younger participants, offering hope that it will be effective in people considered to be at high risk for severe complications from the coronavirus. The analysis looked at subjects given the 100-microgram dose being tested in the much larger Phase III …

CNN reports: The first Phase 3 clinical trial of a coronavirus vaccine in the United States began Monday. The investigational vaccine was developed by the biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial is to be conducted at nearly 100 US research sites, according to Moderna. The …

The New York Times reports: An experimental coronavirus vaccine made by the biotech company Moderna provoked a promising immune response against the virus and appeared safe in the first 45 people who received it, researchers reported on Tuesday in The New England Journal of Medicine. Moderna’s vaccine, developed with researchers at the National Institute of Allergy and Infectious Diseases, was …

Axios reports: The National Institutes of Health may own intellectual property that undergirds a leading coronavirus vaccine being developed by Moderna, according to documents obtained by Axios and an analysis from Public Citizen. Because the federal government has an actual stake in this vaccine, it could try to make the vaccine a free or low-cost public good with wide distribution, …

The Hill reports: The former drug company executive leading the Trump administration’s coronavirus vaccine initiative said he will divest all his shares in Moderna, one of the initiative’s leading candidates. At the time of his appointment to lead “Operation Warp Speed,” the shares were worth about $10 million. The announcement comes as Moderna’s stock soared almost 20 percent on Monday, …

CNBC reports: Moderna’s closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday. Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg dose at both vaccinations, with 15 people in each dose group. Study participants received two doses of the potential vaccine via intramuscular …